InsiderTrades

Form 4 for ANTX AN2 Therapeutics, Inc.

Accepted 2022-06-24 00:00:00 ET · period of report 2022-06-06 · accession 0000899243-22-024050 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
2022-06-24 2022-06-06 ANTX Adjuvant Global Health Technology Fund, L.P. 10% J - Other $15.00 -26.5K 2.18M -1% -$397.7K
I 2022-06-24 2022-06-06 ANTX Adjuvant Global Health Technology Fund, L.P. 10% J - Other $15.00 +26.5K 413.2K +7% +$397.7K

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2022-06-06 J D 26,511 $15.00 2,184,224 D By Adjuvant Global Health Technology Fund DE, L.P. — — (F1) On June 6, 2022, Adjuvant Global Health Technology Fund, L.P. ("AGHT Fund") transferred to Adjuvant Global Health Technology Fund DE, L.P. ("AGHT Fund DE") 26,511 shares of the Issuer's common stock, with a value of $15.00 per share, which is the per share cost of the shares acquired by AGHT Fund. (F2) Shares held directly by AGHT Fund. The sole general partner of AGHT Fund is Adjuvant Capital GP, L.P. ("AC GP") and the sole general partner of AC GP is Adjuvant Capital Management, L.L.C. ("AC MGMT"). Kabeer Aziz, a member of the Issuer's board of directors, is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities. (F3) Shares held directly by AGHT Fund DE. The sole general partner of AGHT Fund DE is AC GP and the sole general partner of AC GP is AC MGMT. Kabeer Aziz, a member of the Issuer's board of directors, is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities.
2 Common Common Stock 2022-06-06 J A 26,511 $15.00 413,156 I — — (F1) On June 6, 2022, Adjuvant Global Health Technology Fund, L.P. ("AGHT Fund") transferred to Adjuvant Global Health Technology Fund DE, L.P. ("AGHT Fund DE") 26,511 shares of the Issuer's common stock, with a value of $15.00 per share, which is the per share cost of the shares acquired by AGHT Fund.